Amenamevir shortens the healing time of recurrent herpes labialis lesions

A single dose of amenamevir 1200mg given within 6 hours of the onset of prodromal symptoms significantly accelerated the healing of all lesions in recurrent herpes labialis, says a latest study. This study was published in the Journal of Dermatology.
This randomized, double-blind, placebo-controlled trial included adult immunocompetent patients with recurrent herpes labialis who experienced and had the ability to recognise prodromal symptoms. Participants were randomly assigned to one of two groups based on the therapy they received: amenamevir 1200mg or a placebo. The primary endpoint of the study was the healing time of all herpes labialis lesions.
According to the results, the median time for all lesions to heal was 5.1 days for amenamevir and 5.5 days for a placebo. When compared to placebo, amenamevir significantly reduced the time it took for all lesions to crust.
Therefore, amenamevir significantly decreased the healing time of lesions of recurrent herpes labialis with clinically no important safety concerns.